Profound sedation, respiratory depression, coma, and death may result from the concomitant use of Buprenex with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol).
The MOU is developed through a process of negotiation and mutual assent, finalized through acceptance of the MOU instrument, and approved by the appropriate agency representatives who signify such approval by signing the MOU.
The MOU aims to enhance the cooperation between. and CTO in areas such as the preparation of regional strategies and action plans for the development of sustainable tourism, the promotion of tourism investment, market intelligence and capacity building.